KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers

May 11, 2020 10:30 am

By Ian Ingram

For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.

Among women treated with … Read more

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I

April 27, 2020 10:20 am

BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its

Read more

Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7, 2020 10:00 am

By Denise Myshko

Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more

First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors

March 27, 2020 12:30 pm

By Matthew Stenger

In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer

July 23, 2019 5:00 pm

By Dave Levitan

A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.

“Up to … Read more

Treating Ovarian Cancers by Targeting Mutations

July 31, 2018 11:22 pm

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more